359 related articles for article (PubMed ID: 24380129)
1. Legal and regulatory aspects of orphan drugs.
Shani S; Yahalom Z
Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():110-5. PubMed ID: 24380129
[TBL] [Abstract][Full Text] [Related]
2. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
3. Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products.
Dear JW; Lilitkarntakul P; Webb DJ
Br J Clin Pharmacol; 2006 Sep; 62(3):264-71. PubMed ID: 16934041
[TBL] [Abstract][Full Text] [Related]
4. Orphan drugs and orphan tests in the USA.
Thoene JG
Community Genet; 2004; 7(4):169-72. PubMed ID: 15692190
[No Abstract] [Full Text] [Related]
5. Developing treatments for inborn errors: incentives available to the clinician.
Haffner ME
Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
[TBL] [Abstract][Full Text] [Related]
6. EU orphan regulation--ten years of application.
Michaux G
Food Drug Law J; 2010; 65(4):639-69, i-ii. PubMed ID: 24479246
[TBL] [Abstract][Full Text] [Related]
7. Orphan drug legislation: lessons for neglected tropical diseases.
Villa S; Compagni A; Reich MR
Int J Health Plann Manage; 2009; 24(1):27-42. PubMed ID: 18435430
[TBL] [Abstract][Full Text] [Related]
8. "Creating hope" and other incentives for drug development for children.
Connor E; Cure P
Sci Transl Med; 2011 Jan; 3(66):66cm1. PubMed ID: 21248312
[TBL] [Abstract][Full Text] [Related]
9. When everyone is an orphan: against adopting a U.S.-styled orphan drug policy in Canada.
Herder M
Account Res; 2013; 20(4):227-69. PubMed ID: 23805831
[TBL] [Abstract][Full Text] [Related]
10. [Orphan drugs--medications for patients with rare diseases].
Thielke D; Thyssen JP; Hansen BJ
Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
[TBL] [Abstract][Full Text] [Related]
11. Rare diseases, orphan drugs, and orphaned patients.
Scheindlin S
Mol Interv; 2006 Aug; 6(4):186-91. PubMed ID: 16960139
[No Abstract] [Full Text] [Related]
12. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
13. Translation of rare disease research into orphan drug development: disease matters.
Heemstra HE; van Weely S; Büller HA; Leufkens HG; de Vrueh RL
Drug Discov Today; 2009 Dec; 14(23-24):1166-73. PubMed ID: 19818412
[TBL] [Abstract][Full Text] [Related]
14. The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.
Burke KA; Freeman SN; Imoisili MA; Coté TR
Clin Pharmacol Ther; 2010 Oct; 88(4):449-53. PubMed ID: 20856241
[TBL] [Abstract][Full Text] [Related]
15. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
Pariser AR; Xu K; Milto J; Coté TR
Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
[TBL] [Abstract][Full Text] [Related]
16. [Orphan drugs: some legal, ethical and economics aspects].
Pabst JY
Rev Epidemiol Sante Publique; 2001 Sep; 49(4):387-96. PubMed ID: 11567205
[TBL] [Abstract][Full Text] [Related]
17. Evaluating The Impact Of The Orphan Drug Act's Seven-Year Market Exclusivity Period.
Sarpatwari A; Beall RF; Abdurrob A; He M; Kesselheim AS
Health Aff (Millwood); 2018 May; 37(5):732-737. PubMed ID: 29733729
[TBL] [Abstract][Full Text] [Related]
18. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
Vegter S; Rozenbaum MH; Postema R; Tolley K; Postma MJ
Clin Ther; 2010 Aug; 32(9):1651-61. PubMed ID: 20974323
[TBL] [Abstract][Full Text] [Related]
19. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
Wellman-Labadie O; Zhou Y
Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435
[TBL] [Abstract][Full Text] [Related]
20. Rare diseases and orphan drugs.
Taruscio D; Capozzoli F; Frank C
Ann Ist Super Sanita; 2011; 47(1):83-93. PubMed ID: 21430345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]